60 Degrees Pharmaceuticals Inc
NASDAQ:SXTP
60 Degrees Pharmaceuticals Inc
Research & Development
60 Degrees Pharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
6
|
60 Degrees Pharmaceuticals Inc
NASDAQ:SXTP
|
Research & Development
-$5m
|
CAGR 3-Years
3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
60 Degrees Pharmaceuticals Inc
Glance View
60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. The company is headquartered in Washington, Washington Dc and currently employs 2 full-time employees. The company went IPO on 2023-07-12. The firm is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Its lead product, ARAKODA (tafenoquine), is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. The firm's pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases; new products that contain the Arakoda regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. The ARAKODA regimen of tafenoquine is in Phase II study data in patients with mild-moderate COVID-19 disease. The company is also planning a clinical study to assess the utility of ARAKODA as a treatment for human babesiosis. The firm is also developing Celgosivir for the treatment of COVID-19, respiratory syncytial virus (RSV), and dengue.
See Also
What is 60 Degrees Pharmaceuticals Inc's Research & Development?
Research & Development
-5m
USD
Based on the financial report for Dec 31, 2024, 60 Degrees Pharmaceuticals Inc's Research & Development amounts to -5m USD.
What is 60 Degrees Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 3Y
3%
Over the last year, the Research & Development growth was -621%. The average annual Research & Development growth rates for 60 Degrees Pharmaceuticals Inc have been 3% over the past three years .
